MedTrace Logo

AMAP102 - Safety, Tolerability and Pharmacokinetics in Healthy Subjects

NCT00995605 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-10-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether AMAP102 is safe and well tolerated by humans.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AMAP102

AMAP102 or Placebo

Sponsors & Collaborators

  • AnaMar AB

    lead INDUSTRY

Principal Investigators

  • Dr Joseph Chiesa, MD FFPM FICR CSci · Covance

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00995605 on ClinicalTrials.gov